189 related articles for article (PubMed ID: 17178785)
21. Secreted bacterial phospholipase A2 enzymes: better living through phospholipolysis.
Sitkiewicz I; Stockbauer KE; Musser JM
Trends Microbiol; 2007 Feb; 15(2):63-9. PubMed ID: 17194592
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 4,5-bisphosphate is a novel coactivator of the Pseudomonas aeruginosa cytotoxin ExoU.
Tyson GH; Hauser AR
Infect Immun; 2013 Aug; 81(8):2873-81. PubMed ID: 23716613
[TBL] [Abstract][Full Text] [Related]
23. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU.
Sato H; Feix JB; Hillard CJ; Frank DW
J Bacteriol; 2005 Feb; 187(3):1192-5. PubMed ID: 15659695
[TBL] [Abstract][Full Text] [Related]
24. Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.
Veesenmeyer JL; Howell H; Halavaty AS; Ahrens S; Anderson WF; Hauser AR
Infect Immun; 2010 Aug; 78(8):3346-57. PubMed ID: 20479080
[TBL] [Abstract][Full Text] [Related]
25. Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection.
McMorran B; Town L; Costelloe E; Palmer J; Engel J; Hume D; Wainwright B
Infect Immun; 2003 Oct; 71(10):6035-44. PubMed ID: 14500525
[TBL] [Abstract][Full Text] [Related]
26. ExoU modulates soluble and membrane-bound ICAM-1 in Pseudomonas aeruginosa-infected endothelial cells.
Lins RX; de Assis MC; Mallet de Lima CD; Freitas C; Maciel Plotkowski MC; Saliba AM
Microbes Infect; 2010 Feb; 12(2):154-61. PubMed ID: 19931407
[TBL] [Abstract][Full Text] [Related]
27. Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aeruginosa requires the phospholipase domain of exoU.
Ramirez JC; Fleiszig SM; Sullivan AB; Tam C; Borazjani R; Evans DJ
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):448-53. PubMed ID: 22167094
[TBL] [Abstract][Full Text] [Related]
28. ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells.
Plotkowski MC; Feliciano LF; Machado GB; Cunha LG; Freitas C; Saliba AM; de Assis MC
Eur Respir J; 2008 Dec; 32(6):1591-8. PubMed ID: 18684846
[TBL] [Abstract][Full Text] [Related]
29. Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis.
Zhu H; Conibear TC; Bandara R; Aliwarga Y; Stapleton F; Willcox MD
Curr Eye Res; 2006 Apr; 31(4):297-306. PubMed ID: 16603462
[TBL] [Abstract][Full Text] [Related]
30. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia.
Howell HA; Logan LK; Hauser AR
mBio; 2013 Mar; 4(2):e00032-13. PubMed ID: 23481600
[TBL] [Abstract][Full Text] [Related]
31. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU.
Rabin SD; Hauser AR
Infect Immun; 2005 Jan; 73(1):573-82. PubMed ID: 15618197
[TBL] [Abstract][Full Text] [Related]
32. Identification and Verification of Ubiquitin-Activated Bacterial Phospholipases.
Tessmer MH; Anderson DM; Pickrum AM; Riegert MO; Frank DW
J Bacteriol; 2019 Feb; 201(4):. PubMed ID: 30455285
[TBL] [Abstract][Full Text] [Related]
33. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection.
Lee VT; Smith RS; Tümmler B; Lory S
Infect Immun; 2005 Mar; 73(3):1695-705. PubMed ID: 15731070
[TBL] [Abstract][Full Text] [Related]
34. Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU.
Saliba AM; de Assis MC; Nishi R; Raymond B; Marques Ede A; Lopes UG; Touqui L; Plotkowski MC
Microbes Infect; 2006 Feb; 8(2):450-9. PubMed ID: 16293434
[TBL] [Abstract][Full Text] [Related]
35. Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.
Hu H; Harmer C; Anuj S; Wainwright CE; Manos J; Cheney J; Harbour C; Zablotska I; Turnbull L; Whitchurch CB; Grimwood K; Rose B;
Clin Microbiol Infect; 2013 Mar; 19(3):266-72. PubMed ID: 22329595
[TBL] [Abstract][Full Text] [Related]
36. ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during
Hardy KS; Tuckey AN; Renema P; Patel M; Al-Mehdi AB; Spadafora D; Schlumpf CA; Barrington RA; Alexeyev MF; Stevens T; Pittet JF; Wagener BM; Simmons JD; Alvarez DF; Audia JP
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202178
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of a phospholipase A1 activity type three secreted protein, PP_ExoU from Pseudomonas plecoglossicida NB2011, the causative agent of visceral granulomas disease in large yellow croaker (Larimichthys crocea).
Zhang J; Wang Y; Guo H; Mao Z; Ge C
J Fish Dis; 2017 Jun; 40(6):831-840. PubMed ID: 27734506
[TBL] [Abstract][Full Text] [Related]
38. Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa.
Kulasekara BR; Kulasekara HD; Wolfgang MC; Stevens L; Frank DW; Lory S
J Bacteriol; 2006 Jun; 188(11):4037-50. PubMed ID: 16707695
[TBL] [Abstract][Full Text] [Related]
39. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
40. [Carriage of the Pseudomonas aeruginosa virulence factors and prognosis after infection].
Zhao RZ; Zheng YJ; Chen Q
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):672-7. PubMed ID: 23158816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
